Cargando…

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report

INTRODUCTION: Although there is a considerable amount of data in the literature on safe discontinuation of first-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia, little is known about discontinuation of second-generation tyrosine kinase inhibitor therapy. Most...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caocci, Giovanni, Greco, Marianna, La Nasa, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160914/ https://www.ncbi.nlm.nih.gov/pubmed/25194418 http://dx.doi.org/10.1186/1752-1947-8-295

Ejemplares similares

Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
por: Greco, Marianna, et al.
Publicado: (2013)

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
por: Galimberti, Sara, et al.
Publicado: (2017)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Mulas, Olga, et al.
Publicado: (2021)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

How We Manage Invasive Fungal Disease in Acute Myeloid Leukemia Patients with Glucose 6 Dehydrogenase Deficiency
por: Sanna, Marco, et al.
Publicado: (2017)

Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation
por: Mulas, Olga, et al.
Publicado: (2022)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Early Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3 Isoform, FLT3-ITD Mutation, and Elevated WT1 Level
por: Greco, Marianna, et al.
Publicado: (2013)

Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
por: Caocci, Giovanni, et al.
Publicado: (2020)

Bone Marrow Homing and Engraftment Defects of Human Hematopoietic Stem and Progenitor Cells
por: Caocci, Giovanni, et al.
Publicado: (2017)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
por: Caocci, Giovanni, et al.
Publicado: (2016)

Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation
por: Sanna, Marco, et al.
Publicado: (2013)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
por: Al-Dubai, Husam N., et al.
Publicado: (2020)

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
por: Kiriyama, Hiroyuki, et al.
Publicado: (2019)

Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature
por: Sekiguchi, Yasunobu, et al.
Publicado: (2015)

Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia
por: Chan, Justine, et al.
Publicado: (2019)

Nilotinib-Induced Elephantine Psoriasis In a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review
por: Sadatmadani, Seyedeh Fatemeh, et al.
Publicado: (2022)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine
por: Galitzia, Andrea, et al.
Publicado: (2022)

Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant
por: Onaka, Takashi, et al.
Publicado: (2017)

Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia
por: Ismail, Abdel-Latif S, et al.
Publicado: (2020)

Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report
por: Centrone, Renato, et al.
Publicado: (2020)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
por: Kim, Da Jung, et al.
Publicado: (2019)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
por: Cengiz Seval, Güldane, et al.
Publicado: (2017)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_8iblp3h2fmsn5ge3i499mtgepo